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Abstract
Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system.
Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients
[(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications
were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid
tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen
before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after
many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing
slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other
nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for
thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modiﬁed
T cells is type of cell therapy with the fastest growth. These annual reports reﬂect current activity and trends and are useful
for health-care planning.
Introduction
Hematopoietic cell transplantation (HCT) is an established
procedure for many inherited or acquired disorders of the
hematopoietic system, whether benign or neoplastic,
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including those of the immune system, and as enzyme
replacement in metabolic disorders [1–4]. The activity
survey of the European Society of Blood and Marrow
Transplantation (EBMT), describing the status of HCT in
Europe and afﬁliated countries, has become an instrument
to observe trends and to monitor changes in technology
[5–14]. The survey using a standardized structure captures
the numbers of HCT from highly committed participating
teams, divided by indication, donor type, and stem cell
source. More recently, the survey has included information
on novel cell therapies with hematopoietic stem cells for
non-hematopoietic use, and the use of non-hematopoietic
stem and progenitor cells. This coincides with the interest of
the World Health Organization (WHO; www.who.org) in
cell and tissue transplants, and further stresses the need for
adequate and timely information [15]. The analysis of the
survey data spanning 27 years and amassing data on almost
708,000 transplants in over 630,000 patients has shown a
continued and constant increase in the annual numbers of
HCT and transplant rates for both allogeneic and autologous
HCT. This report is based on the 2017 survey data. In
addition to transplant rates and indications, it focuses on
more recent changes possibly related to development of
alternative therapies.
Patients and methods
Data collection and validation
Participating teams were invited to report their data for 2017
as listed in Table 1. The survey allows the possibility to
report additional information on the numbers of subsequent
transplants performed because of relapse, rejection, or those
that are part of a planned sequential transplant protocol.
Additional information on the numbers of donor lym-
phocyte infusions (DLIs), reduced intensity HCT, and the
numbers of pediatric HCT is also collected. Quality control
measures included several independent systems: conﬁrma-
tion of validity of the entered data by the reporting team,
selective comparison of the survey data with MED-A data
sets in the EBMT Registry database, and crosschecking
with the National Registries.
Teams
A total of 720 centers from 50 countries were contacted for
the 2017 survey (40 European and 10 afﬁliated countries);
of which 683 teams reported. This corresponds to a 95%
return rate and includes 83% EBMT members and 17%
non-EBMT members. Thirty-seven active teams failed to
report in 2017. Reporting teams are listed in the online
appendix in alphabetical order by country, city, and EBMT
center code, with their reported numbers of ﬁrst and total
HCT, and of ﬁrst allogeneic and autologous HCT as sup-
plementary material. The WHO regional ofﬁce deﬁnitions
were used to classify countries as European or non-
European. Nine neighboring non-European countries parti-
cipated in the 2017 EBMT survey: Algeria, Iraq, Iran,
Israel, Jordan, Lebanon, Saudi Arabia, South Africa, and
Tunisia. Their data, 3101 HCT in 2948 patients, from 30
actively transplanting teams make up 6.9% of the total data
set and are included in all analyses.
Patient and transplant numbers
Wherever appropriate, patient numbers corresponding to the
number of patients receiving a ﬁrst transplant, and trans-
plant numbers reﬂecting the total number of transplants
performed are listed. The term sibling donor includes
human leukocyte antigen (HLA) identical siblings and
twins but not siblings with HLA mismatches. Unrelated
donor transplants include HCT from matched or mis-
matched unrelated donors with peripheral blood and mar-
row as a stem cell source but not cord blood HCT.
Haploidentical transplants are being described as any family
member with 2 or more loci mismatch within the loci HLA-
A, -B, -C, -DRB1, and -DQB1 in graft versus host (GvH)
and/or host versus graft direction. Other family member
donors are those related donors that are mismatched to a
lesser degree than a full haplotype. Additional non-ﬁrst
transplants may include multiple transplants deﬁned as
subsequent transplants within a planned double or triple
autologous or allogeneic transplant protocol, and re-
transplants (autologous or allogeneic) deﬁned as unplan-
ned HCT for rejection or relapse after a previous HCT.
Transplant rates
Transplant rates, deﬁned as the total number of HCT per 10
million inhabitants, were computed for each country with-
out adjustments for patients who crossed borders and
received their HCT in a foreign country. Population num-
bers for the European countries in 2017 were obtained from
Eurostats (http://epp.eurostat.ec.europa.eu) and from the US
census bureau database for the non-European countries
(https://www.census.gov/data-tools).
Analysis
Wherever appropriate, the absolute numbers of transplanted
patients, transplants, or transplant rates are shown for spe-
ciﬁc countries, indications, or transplant techniques. Mye-
loid malignancies include acute myeloid leukemia (AML),
myelodysplastic or myelodysplastic/myeloproliferative
neoplasm (MDS or MD/MPN overlap), myeloproliferative
J. R. Passweg et al.
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neoplasm (MPN), and chronic myeloid leukemia (CML).
Lymphoid malignancies include acute lymphocytic leuke-
mia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin
lymphoma (HL), non-Hodgkin lymphoma (NHL), and
plasma cell disorders (PCD including multiple myeloma
(MM) and others). The nonmalignant disorders include
bone marrow failure (BMF including severe aplastic anemia
(SAA) and others), thalassemia and sickle cell disease
(HG), primary immune disease, inherited disease of meta-
bolism, and autoimmune disease (AID). Others include
histiocytosis and rare disorders not included in the above.
BMF syndromes were grouped until 2004, at which time
they were separated into SAA and other marrow failure.
Trends shown over time include changes in absolute num-
ber of patients transplanted from 1990 to 2017. We use
graphical representation to indicate changes over time. We
consider an increase or decrease of ±5% as a non-relevant
change. To conﬁrm trends we used SPSS to automatically
ﬁt the best exponentially smoothed, autoregressive inte-
grated moving average model without any further pre-
speciﬁcation. To detect possible deviations from trends, we
calculated the observed and predicted counts as well as the
95% conﬁdence intervals (CIs).
Results
Participating teams in 2017
Of the 683 teams, 430 (63%) performed both allogeneic and
autologous transplants; 236 (34%) restricted their activity to
autologous HCT, and 17 (2%) to allogeneic transplants
only. Of the 683 active centers, 131 (19%) centers per-
formed transplants on both adult and pediatric patients. An
additional 115 (17%) centers were dedicated pediatric
transplant centers and 437 (64%) centers performed trans-
plants on adults only. Thirty-seven teams failed to report in
2017, which when compared to previously reported data by
these teams, accounts for approximately 630 non-reported
HCT.
Numbers of patients and transplants
In 2017, 45,418 transplants were reported in 41,100 patients
(ﬁrst transplant); of these, 18,281 HCT (40%) were allo-
geneic and 27,137 (60%) autologous (Table 1). When
compared with 2016 the total number of transplants
increased by 4.1% (3.6% allogeneic HCT and 4.4% auto-
logous HCT) [16]. In patients receiving their ﬁrst transplant
in 2017, the increase was 3.9% for allogeneic HCT and
5.0% for autologous HCT. In addition, there were
4318 second or subsequent transplants, 1126 being allo-
geneic, mainly to treat relapse or graft failure and 3192
autologous, the majority of which were most likely part of
multiple transplant procedures such as either tandem pro-
cedures, or as salvage autologous transplants for plasma cell
disorders. Furthermore, 986 of the allogeneic HCTs were
reported as being given after a previous autologous HCT,
and were mainly for lymphoma or plasma cell disorders.
The total number of patients transplanted under the age
of 18 in both dedicated and joint adult-pediatric units was
5056 (3725 allogeneic and 1331 autologous). This is an
increase of 7.8% (5.1% allogeneic and 16.2% autologous)
when compared to 2016, where 4690 HCT (3545 allogeneic
and 1145 autologous) were reported. From the 5056
patients, 3983 transplants in 3505 patients (2701 allogeneic,
77%; and 804 autologous, 23%) were performed in dedi-
cated pediatric centers. Due to limitations in the design of
the survey, indication for HCT can only be observed in the
dedicated pediatric centers. The main indications were
myeloid malignancies 588 (17%; 99% allogeneic), lym-
phoid malignancies 851 (24%; 86% allogeneic), solid
tumors 696 (20%; 4% allogeneic), and nonmalignant dis-
orders 1370 (39%; 99% allogeneic). When compared to
2016, increases in allogeneic HCT were seen in sickle cell
disease (55.8%), thalassemia (40.4%), ALL (12.8%), and
AML (9.6%). For autologous HCT the main increase was
seen in HL (30%) and pediatric solid tumors (17.5%).
Indications and trends
Indications for HCT in 2017 are listed in detail in Table 1.
Main indications for HCT were myeloid malignancies
(AML, CML, MDS or MD/MPN overlap, and MPN):
10,147 (25% of total; 96% of which were allogeneic);
lymphoid malignancies (ALL, CLL, HL, NHL, and PCD):
26,488 (64%; 19% allogeneic); solid tumors: 1607 (4%; 2%
allogeneic); nonmalignant disorders: 2667 (7%; 81% allo-
geneic), and others: 191 (0.5%). As seen in previous years,
the majority of HCT for lymphoid malignancies were
autologous, while most transplants for myeloid malig-
nancies were performed using stem cells from allogeneic
donors. Autologous HCT for nonmalignant disorders pre-
dominantly include patients with autoimmune disorders.
Figure 1a, b shows distribution of disease indications for
allogeneic (Fig. 1a) and autologous (Fig. 1b) HCT as a pie
graph. For comparative analyses, the 2017 data are juxta-
posed to the analogous data from the years 2007 and 1997
using the size of the pie graph to represent the absolute
number of transplanted patients and the pie slices for pro-
portions of speciﬁc indications [9, 17]. The 2017 data are
used to depict the pie graph with the 100% size for allo-
geneic and autologous HCT respectively, pie size for 2007
and 1997 are proportionally smaller.
As shown (Fig. 1a), the number of patients treated with
an allogeneic HCT has increased from 4751 to 17,155 over
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2017: 17,155
2007: 10,072
1997: 4,751
2017: 23,945
2007: 15,491
1997: 12199
Acute myeloid leukemia
Chronic myeloid leukemia
Myeloproliferative disorders
Acute lymphatic leukemia
Chronic lymphocytic leukemia
Plasma cell disorder
Hodgkin lymphoma
Non hodgkin lymphoma
Other solid tumor
Bone marrow failure
Primary immune disorders
Others
Auto immune disorders
Inherited disorders of metabolism
Proportion of allogeneic HCT over time
2017
38.9
2.0
16.1
15.6
1.3
2.2
2.6
7.4
0.2
4.7
3.7
3.2
0.9
0.1
0.9
100 100
0.7
0.1
0.8
2.7
2.5
5.2
0.6
8.5
2.8
5.0
3.2
17.7
13.4
4.3
32.5
2007 1997
24.5
25.3
6.8
20.0
0.7
3.2
0.7
4.8
0.3
5.0
2.6
1.7
2.8
0.1
1.6
100
100 100 100
0.7
0.2
0
3.0
21.5
4.3
5.2
25.1
8.7
18.3
3.8
9.2
1997
Proportion of autologous HCT over time
2007
4.5
1.3
42.0
11.8
29.9
4.2
1.9
0.6
2.5
0.1
1.0
0.1
2017
1.6
0.4
53.0
9.0
27.3
3.2
1.6
0.1
1.8
0.1
1.9
0.1
Myeloid disorders
Acute lymphatic and chronic lymphocytic leukemia
Plasma cell disorder
Hodgkin lymphoma
Non hodgkin lymphoma
Pediatric solid tumors
Germ cell tumors
Breast cancer
Others
Non malignant disorders
Other solid tumors
Auto immune disorders
a
b
Hemoglobinopathies
Fig. 1 Relative proportion of disease indications for hematopoietic cell transplantation (HCT) in Europe between the years 1997, 2007, and 2017.
a Relative proportion of allogeneic HCT. b Relative proportion of autologous HCT
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20 years. For allogeneic HCT, AML is the most frequent
indication (39%), of these 56% were for patients in CR1,
29% for patients with more advanced disease, and 15% for
patients with transformed AML, either therapy-related or
from MDS/MPN. The 20-year trend conﬁrms the decline in
HCT for CML from 25.3 to 1.9%, whereas AML, MDS,
and MPN have increased substantially. The proportion of
ALL transplants has decreased only slightly, other lym-
phoid malignancies have rather increased. Compared to
2016, there were increases in allogeneic HCT for AML by
6.3%, and MDS and MPN by 9.5% and 9.0%, respectively.
HL increased by 13.8%, and thalassemia and sickle cell
disease by 27.7% and 56.9%, respectively. Decreases were
seen for CML by 12.8%, PCD by 16.9%, CLL by 16.4%,
and BMF by 10.3%.
In Fig. 1b for autologous HCT, the number of patients
has increased from 12,199 to 23,945 (an increase of 196%
over 20 years as compared to allogeneic HCT where the
increase is 360% over 20 years). In autologous HCT, PCD
is the most frequent indication (53%), of these 51.5% were
for MM. Compared to 2016, there were increases in auto-
logous HCT for AID by 31.9%, neuroblastoma by 12.1%,
soft tissue and Ewing sarcoma by 20.5%, and MM by 7.0%.
In autologous HCT, myeloma has become the dominant
indication increasing from 18 to 53% over the past 20 years.
Proportions of HCTs for HL and NHL have remained
stable. Autologous HCT for AML has decreased from 13 to
1.72%. Already well described is the change in autologous
HCT for solid tumor where the decrease in use of this
technology in breast cancer dominates the graphical
representation.
Within allogeneic HCT 7166 were performed using non-
myeloablative conditioning in 2017. This comprises 39% of
all allogeneic HCT, and has remained stable over the last 9
years. European maps depicting transplant rates by country
are provided in the supplementary ﬁgures section (supple-
mentary Figure 1a for allogeneic, 1b for autologous)
Nonmalignant disorders
Figure 2 depicts allogeneic HCT numbers for nonmalignant
disorders. Since 2016, an increase in numbers of HCT for
hemoglobinopathies (sickle cell disease by 56.9% and tha-
lassemia by 27.7%) and inherited disorders of metabolism
by 6.0% has been observed with stable numbers for primary
immunodeﬁciencies and AID. The increase for sickle cell
disease HCT is clearly (>95% CI for the prediction model)
signiﬁcant, for thalassemia of borderline signiﬁcance. A
decline in the numbers of HCT is seen for BMF by 10.3%.
This decline is still borderline within the lower conﬁdence
limits of the prediction model but after many years of
increasing HCT numbers for marrow failure this is the ﬁrst
time that numbers actually do decline. This is likely due to
the use of thrombopoietin analogs recently approved to treat
refractory aplastic anemia.
Autologous HCT (not shown in the ﬁgure) is pre-
dominantly used for the treatment of AIDs, where a con-
tinuous increase has been seen for the last 12 years.
Compared to 2016, the increase is 32%. This recent increase
is however mainly due to one non-EBMT member center in
Eastern Europe reporting large numbers of autologous HCT
for multiple sclerosis.
We now focus on marrow failure, where Fig. 3a shows
recent changes in practice for BMF: types of donors used
indicate that the use of sibling and unrelated donor transplants
are decreasing by 15% and 8% respectively. Whilst the
numbers of haploidentical HCT for marrow failure remain
stable, the number of cord blood transplants performed is very
low. In marrow failure, the use of marrow is generally
recommended over the use of peripheral blood as a stem cell
source, mainly because of the absence of beneﬁt of potentially
higher alloreactivity conferred by the higher number of T
lymphocytes in the peripheral blood graft [18, 19]. Figure 3b
shows the changes in stem cell source for sibling donor HCT,
3c for unrelated donor HCT, and 3d for haploidentical HCT.
Marrow is the preferred source of stem cells in sibling donor
HCT but is less so in unrelated donor HCT. In haploidentical
HCT for marrow failure, slightly more peripheral blood HCT
is performed when compared to marrow. Marrow failure
syndromes are rare diseases and the experience of teams
doing these transplants is evidently limited. Table 2 shows the
number of transplants for BMF by type of donor and the
number of teams performing these transplants. Of note, e.g.,
in haploidentical HCT the 108 patients receiving transplants
were treated in 64 different centers, the median number of
haploidentical HCT per team is 1 (range 1–9). Over 100
patients received haploidentical HCTs for marrow failure in
spite of a very limited number of published series [20–23] in
the ﬁeld. European maps depicting transplant rates by country
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Fig. 2 Trends in the absolute numbers of allogeneic hematopoietic
cell transplantation (HCT) for nonmalignant disorders in Europe
1990–2017
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are provided in the Supplementary Figures section. Supple-
mentary Figure 1a shows allogeneic transplant rates per
country for all indications. Whereas the map depicting allo-
geneic HCT reﬂects income class of countries, wealthier
countries usually having higher rates than middle-income
countries, transplant rates for marrow failure look somewhat
different. The countries with the highest reported rates for
marrow failure transplants include Lithuania, Norway, Ire-
land, Turkey, and Israel.
Cell therapy
Table 3 shows cell therapies performed in EBMT centers in
2017. There were 2825 patients receiving DLIs, which is a
slight decrease of 1.9% since 2016 where 2879 DLIs were
reported. The majority of DLIs were given for relapse
(1284) and graft enhancement (661). Other reasons being
for residual disease (422) and “per protocol” (458). A total
of 1202 patients received other forms of cell therapy, most
commonly mesenchymal stromal cells (n= 557; 91% allo-
geneic), mainly to treat GvH disease (GvHD). Expanded/
selected T lymphocytes (n= 179; 100% allogeneic) and
genetically modiﬁed T cells (n= 151; 50% allogeneic) were
the second most frequently reported cell therapy. The area
with the highest growth is genetically modiﬁed T cells. The
main indications for cell therapies (excluding DLI) being
GvHD or graft enhancement (n= 688; 95% allogeneic),
malignancy (n= 253; 50% allogeneic), infections (n= 124;
100% allogeneic), AID (n= 61; 43% allogeneic), and
genetic disease (n= 14; 7% allogeneic). The number of cell
therapies have increased by 27.6% since 2015, when they
were ﬁrst introduced into the survey (2015, HCT= 942;
and 2017, HCT= 1202) [24, 25].
Discussion
The EBMT activity survey has been conducted annually
since 1990 [7]. The 2010 survey reported for the ﬁrst time
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Fig. 3 Changes in donor choice and stem cell source for bone marrow
failure in Europe 1990–2017. a Donor choice. b Human leukocyte
antigen identical sibling hematopoietic cell transplantation (HCT) by
bone marrow (BM) or peripheral blood (PB). c Unrelated HCT by BM
or PB. d Haploidentical HCT by BM or PB
Table 2 BMF data by center in 2017
HCT, N Teams, N Median and range
Sibling 363 168 1 (1–20)
Unrelated 317 163 1 (1–8)
Haploidentical 108 64 1 (1–9)
Cord blood 14 14 1 (1)
Total 802
BMF bone marrow failure, HCT hematopoietic cell transplantation
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more than 30,000 patients transplanted in a given year,
>40,000 transplants in 2014, and >45,000 in 2017. As before,
autologous HCT continues to expand (4.4%) and at a higher
rate than allogeneic HCT (3.6%). In allogeneic HCT, some
indications continue to increase but not others. Impressive
changes are observed in nonmalignant disorders, there were
considerable increases of allogeneic HCT for hemoglobino-
pathies, including the thalassemias and sickle cell disease.
The majority of which is with matched sibling donors and
among sibling donor HCT, 73% is with marrow as a stem cell
source. For the ﬁrst time we describe a lower number of
transplants for marrow failure. Such a decrease coincides with
the approval of the thrombopoietin mimetic eltrombopag for
relapsed refractory aplastic anemia [21]. Next to aplastic
anemia, decreased use of allogeneic HCT was also seen in
CLL and PCD by almost 20%, which is best explained by the
competition of new drugs being developed in these
ﬁelds. Therefore, it seems that the use of allogeneic HCT is
modiﬁed by availability of drugs to treat the disease. Fur-
thermore, such shifts in use of transplant technology occur
rather rapidly.
In autologous HCT, the only striking increase is in HCT for
AID, which has increased by almost a third since 2016, mostly
related to autologous HCT to treat multiple sclerosis [26].
We have generated pie graphs showing number of
transplants as pie size and proportion of indications by
segment over the last 20 years. Of interest is that some of
the proportions have remained stable over the years, e.g.,
allogeneic HCT for ALL. While, as described before, CML
has decreased dramatically as a main indication. It appears
to have been replaced in much greater numbers, but in
similar proportions, by MDS and more recently MPN and
AML. Whether this shift in indications is biased by the
availability of treatment resources, or follows some other
logic, is difﬁcult to discern.
For marrow failure, interesting aspects include the reso-
lute resistance in the use of peripheral blood over marrow.
This is seen more so with unrelated donor HCT than with
sibling donor transplantation, and may possibly be related to
the unwillingness of some unrelated donors to undergo
marrow harvest. The use of haploidentical HCT for marrow
failure is not substantiated by much available data, and the
reason for this use of technology may be due to the general
popularity of haploidentical HCT in recent years.
The section on cell therapies shows the gradual
increasing use of mesenchymal stromal cells, most com-
monly to treat GvHD. There is a large increase in the use
of gene modiﬁed T cells from 36 in 2016 to 151 in 2017.
Whether these numbers reﬂect all patients receiving gene-
modiﬁed T cells in Europe during the year is not entirely
clear, as some centers may not report patients treated in
clinical trials. It is our goal to truly reﬂect the activity
of this rapidly growing ﬁeld within Europe. As CAR-T
cells [27] have become commercially available in 2018, it
is most important that EBMT centers continue the well-
established practice of transparently sharing data on
activity of advanced therapy medicinal products manu-
factured from hematopoietic cells used and on the out-
come of patients. These data reﬂect the ability of the
EBMT to capture data not only on HCT but also on non-
HCT cell therapies in this ﬁeld of rapidly emerging
treatment options.
Table 3 Non-HCT cellular therapies using manipulated cells in 2017
Number of patients DLI MSC NK cells Selected/
expanded
T cells or
CIK
TREGS Geneti-
cally
modiﬁed
T cells
Dendritic
cells
Expanded
CD34+
cells
Geneti-
cally
modiﬁed
CD34+
cells
Other
Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto
GvHD 413 5 8 36 13
Graft enhancement 661 55 18 1 14 5 57 4 6 1 44 8
Autoimmune disease 6 14 19 1 21
Genetic disease 1 13
Infection 3 113 8
Malignancy 6 42 24 8 16 78 5 35 2 32 5
DLI for residual
disease
422
DLI for relapse 1284
DLI per protocol 458
Regenerative
medicine
31 11 1 2 2 4 11
Total 2825 509 48 27 0 179 0 65 8 73 78 5 39 11 0 1 13 101 45
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The annual activity survey of the EBMT reﬂects current
activity and trends in the ﬁeld of transplant technology. It is
valuable for the dissemination of the most recent informa-
tion on indications, donor, and stem cell usage, which can
ultimately be beneﬁcial in health care planning.
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